Eptinezumab 100 or 300 mg ev: Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
Study summary
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.
The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III).
* At least 8 days of migraine per month.
* Adequate compliance with study procedures.
* Availability of a migraine diary for at least one month prior to enrollment.
* Ongoing attack before administration.
* Included in the TACHIS study (NCT06409845)
Exclusion Criteria:
* Subjects with contraindications to the use of eptinezumab.
* Concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes.
* Pregnancy and breastfeeding.
* Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.
Primary outcome measure(s)
Time to Headache Pain Freedom — Up to 48 hours postdose Time to headache pain freedom defined as the time that the participant reported freedom of pain, meaning their headache pain had gone from moderate to severe at baseline to no pain.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
